Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 6/20 | 0.49 |
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 2/20 | 0.48 |
| ▸ | THRB | P10828 | 2/20 | 0.43 |
| ▸ | VNN1 | O95497 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
| ▸ | CTSC | P53634 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1383679 | 0.87 | RAPGEF4 (0.38) | EGFRABCG2TSHRHTTKDR | |
| SCHEMBL1383042 | 0.87 | KIF11 (0.53) | EGFRABCG2TSHRHTTKDR | |
| SCHEMBL1383635 | 0.83 | KDR (0.38) | ABCG2KDRMAPT | |
| SCHEMBL1382827 | 0.81 | EGFR (0.48) | EGFRABCG2TSHRHTTKDR | |
| SCHEMBL1383615 | 0.81 | KDR (0.48) | EGFRABCG2TSHRHTTKDR | |
| SCHEMBL7105495 | 0.80 | NPC1 (0.36) | MAPT | |
| SCHEMBL1383229 | 0.79 | GAA (0.40) | KDRTP53MAPT | |
| SCHEMBL1385961 | 0.78 | MEN1 (0.44) | EGFRABCG2HTTKDRCTSC | |
| SCHEMBL1386811 | 0.78 | KDR (0.44) | EGFRABCG2TSHRHTTKDR | |
| SCHEMBL1383890 | 0.78 | GAA (0.37) | KDRLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4837864-B2 | — | — | 2011-12-14 | — | — | JP | claimed |
| US-7323474-B2 | Pyridine derivatives inhibiting angiogenesis and/or VEGF receptor tyrosine kinase | NOVARTIS AG (CH) | 2008-01-29 | — | — | US | claimed |
| EP-1254138-B1 | PYRIDINE DERIVATIVES INHIBITING ANGIOGENESIS AND/OR VEGF RECEPTOR TYROSINE KINASE | NOVARTIS AG (CH) | 2005-05-11 | — | — | EP | claimed |
| US-20040209894-A1 | Pyridine derivatives inhibiting angiogenesis and/or VEGF receptor tyrosine kinase | BOLD GUIDO | 2004-10-21 | — | — | US | claimed |
| US-6706731-B2 | WITH ISOQUINOLINE DERIVATIVES AS ANTITUMOR AGENTS | NOVARTIS AG (CH) | 2004-03-16 | — | — | US | claimed |
| US-20030158409-A1 | Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase | NOVARTIS AG (CH) | 2003-08-21 | — | — | US | claimed |
| EP-1254138-A1 | PYRIDINE DERIVATIVES INHIBITING ANGIOGENESIS AND/OR VEGF RECEPTOR TYROSINE KINASE | Novartis AG (CH) | 2002-11-06 | — | — | EP | claimed |
| WO-2001058899-A1 | PYRIDINE DERIVATIVES INHIBITING ANGIOGENESIS AND/OR VEGF RECEPTOR TYROSINE KINASE | NOVARTIS AG (CH) | 2001-08-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209894-A1 | Pyridine derivatives inhibiting angiogenesis and/or VEGF receptor tyrosine kinase | FLT1, FLT4, KDR | EGFR 15/4885ABCG2 835/4885TSHR 1449/4885 |
| US-20030158409-A1 | Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase | FLT1, FLT4, KDR | EGFR 12/4885ABCG2 585/4885TSHR 1241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.